Drug Topics April 10, 2025
Pharmacists have positive impacts on health outcomes for diabetes and patients using CGM devices, including reductions in A1c.
The FDA cleared the new Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for patients 18 years and older with diabetes. The device builds on the performance of other Dexcom CGMs and has an overall mean absolute relative difference (MARD) of 8%, which increases the accuracy over other CGMs.1
“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” Jake Leach, executive vice president and chief operating officer at Dexcom, said in a news release.1 “By listening to the needs of our users, we’re proud to offer the longest lasting wearable and most accurate CGM, giving people the...
Today's Sponsors
Today's Sponsor